Traws Pharma, Inc. (TRAW)
$0.60+$0.01 (+2.14%) Today
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib. The company has four clinical programs: (i) tivoxavir marboxil, (ii) ratutrelvir, (iii) narazaciclib (ON 123300), and (iv) rigosertib. It is focused on the development of tivoxavir marboxil and ratutrelvir. The company derives revenue from its collaboration and licensing agreements.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Grant or award | 10 | 708,750 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
45 Form 4 filings on record, the earliest from Apr 2, 2025, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Charles David Pauza - Officer | Grant or award | Stock Option (right to buy) | 97,000 | $0.00 | - | |
| Werner Cautreels | Grant or award | Stock Option (right to buy) | 14,150 | $0.00 | - | |
| Nikolay Savchuk - Officer | Grant or award | Stock Option (right to buy) | 93,000 | $0.00 | - | |
| Jack E. Stover | Grant or award | Stock Option (right to buy) | 14,150 | $0.00 | - | |
| Iain D. Dukes - Officer | Grant or award | Stock Option (right to buy) | 274,000 | $0.00 | - | |
| Robert Redfield - Officer | Grant or award | Stock Option (right to buy) | 84,000 | $0.00 | - | |
 Charles Nolan Parker - Officer | Grant or award | Stock Option (right to buy) | 90,000 | $0.00 | - | |
| Mary Teresa Shoemaker | Grant or award | Stock Option (right to buy) | 14,150 | $0.00 | - | |
| Trafford Clarke | Grant or award | Stock Option (right to buy) | 14,150 | $0.00 | - | |
| John Harold Leaman | Grant or award | Stock Option (right to buy) | 14,150 | $0.00 | - | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Common Stock | 597,729 | $1.67 | $998K | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Series A Warrants (right to buy) | 597,729 | - | - | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Series B Warrants (right to buy) | 597,729 | - | - | |
| ORBIMED ADVISORS LLC - 10% Owner | Open-market purchase | Series C Warrants (right to buy) | 1,793,187 | - | - | |
| Charles Nolan Parker - Officer | Grant or award | Stock Option (right to buy) | 104,544 | $0.00 | - | |
| Charles Nolan Parker - Officer | Grant or award | Common Stock | 15,393 | $0.00 | - | |
| Charles Nolan Parker - Officer | Grant or award | Stock Option (right to buy) | 32,406 | $0.00 | - | |
| Charles Nolan Parker - Officer | Grant or award | Stock Option (right to buy) | 61,571 | $0.00 | - | |
| Trafford Clarke | Grant or award | Stock Option (right to buy) | 33,435 | $0.00 | - | |
| Werner Cautreels | Grant or award | Stock Option (right to buy) | 31,258 | $0.00 | - | |
| John Harold Leaman | Grant or award | Stock Option (right to buy) | 33,435 | $0.00 | - | |
| Iain D. Dukes - Officer | Grant or award | Stock Option (right to buy) | 231,336 | $0.00 | - | |
| Charles David Pauza - Officer | Grant or award | Stock Option (right to buy) | 118,367 | $0.00 | - | |
| Nikolay Savchuk - Officer | Grant or award | Stock Option (right to buy) | 96,899 | $0.00 | - | |
| Jack E. Stover | Grant or award | Stock Option (right to buy) | 33,435 | $0.00 | - | |
| Robert Redfield - Officer | Grant or award | Stock Option (right to buy) | 108,854 | $0.00 | - | |
| Mary Teresa Shoemaker | Grant or award | Stock Option (right to buy) | 33,435 | $0.00 | - | |
| Trafford Clarke | Grant or award | Common Stock | 6,157 | $0.00 | - | |
| Trafford Clarke | Grant or award | Stock Option (right to purchase) | 24,629 | $0.00 | - | |
| Iain D. Dukes - Officer | Grant or award | Common Stock | 36,943 | $0.00 | - | |
| Iain D. Dukes - Officer | Grant or award | Stock Option (right to purchase) | 147,771 | $0.00 | - | |
| Nikolay Savchuk - Officer | Grant or award | Common Stock | 16,419 | $0.00 | - | |
| Nikolay Savchuk - Officer | Grant or award | Stock Option (right to purchase) | 65,676 | $0.00 | - | |
| Robert Redfield - Officer | Grant or award | Common Stock | 16,419 | $0.00 | - | |
| Robert Redfield - Officer | Grant or award | Stock Option (right to purchase) | 65,676 | $0.00 | - | |
| Charles David Pauza - Officer | Grant or award | Common Stock | 18,471 | $0.00 | - | |
| Charles David Pauza - Officer | Grant or award | Stock Option (right to purchase) | 73,886 | $0.00 | - | |
| John Harold Leaman | Grant or award | Common Stock | 4,058 | $0.00 | - | |
| John Harold Leaman | Grant or award | Stock Option (right to purchase) | 16,234 | $0.00 | - | |
| Mary Teresa Shoemaker | Grant or award | Common Stock | 6,157 | $0.00 | - | |
| Mary Teresa Shoemaker | Grant or award | Stock Option (right to purchase) | 24,629 | $0.00 | - | |
| Werner Cautreels | Grant or award | Common Stock | 4,874 | $0.00 | - | |
| Werner Cautreels | Grant or award | Stock Option (right to purchase) | 19,496 | $0.00 | - | |
| Jack E. Stover | Grant or award | Common Stock | 6,157 | $0.00 | - | |
| Jack E. Stover | Grant or award | Stock Option (right to purchase) | 24,629 | $0.00 | - |
Traws Pharma, Inc. (TRAW) had 10 insider filings in the last 90 days, with the most recent on 2026-07-16. The full record for TRAW runs to 45 Form 4 filings, the earliest from 2025-04-02. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of TRAW were filed in the last 90 days. 4 purchases are on record for this company.
No insider sales of TRAW were filed in the last 90 days.
This page tracks TRAW Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add TRAW to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
